
## Duncan E Scott

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8099368/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase Î <sup>3</sup> Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode. Journal of Medicinal Chemistry, 2022, 65, 3359-3370.	6.4	14
2	A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death. Cell Chemical Biology, 2021, 28, 835-847.e5.	5.2	27
3	Systematic Investigation of the Permeability of Androgen Receptor PROTACs. ACS Medicinal Chemistry Letters, 2020, 11, 1539-1547.	2.8	40
4	Small molecules, big targets: drug discovery faces the protein–protein interaction challenge. Nature Reviews Drug Discovery, 2016, 15, 533-550.	46.4	806
5	Engineering Archeal Surrogate Systems for the Development of Protein–Protein Interaction Inhibitors against Human RAD51. Journal of Molecular Biology, 2016, 428, 4589-4607.	4.2	13
6	Structureâ€activity relationship of the peptide bindingâ€motif mediating the BRCA2:RAD51 protein–protein interaction. FEBS Letters, 2016, 590, 1094-1102.	2.8	20
7	Smallâ€Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases. ChemMedChem, 2015, 10, 296-303.	3.2	36
8	Using a Fragmentâ€Based Approach To Target Protein–Protein Interactions. ChemBioChem, 2013, 14, 332-342.	2.6	115
9	Fragment-Based Approaches in Drug Discovery and Chemical Biology. Biochemistry, 2012, 51, 4990-5003.	2.5	370
10	Drugging challenging targets using fragment-based approaches. Current Opinion in Chemical Biology, 2010, 14, 299-307.	6.1	82